aplitabart

A recombinant agonistic pentameric immunoglobulin M (IgM) monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, aplitabart, containing ten binding sites specific for DR5, specifically targets and binds to DR5, which mimics the interaction of DR5 with its natural ligand TRAIL. This cross-links and activates DR5 receptors, and activates the death receptor signaling pathway. This results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.